MOB

Moberg Pharma

Market Cap 514.5M

Moberg Pharma AB is a Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal, Kerasal Nail, Balmex, New Skin, Dermoplast and Domeboro. Kerasal Nail is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm.

+ more

Redeye Research

Reports

Notes

Today
Day High
29.50
28.8
Day Low
28.20
Day Open
28.50
Prev Close
29.50
VWAP
28.7
Volume
127K
Turnover
3.661M
Top Broker
CAR
VWAP
29.1
Avg Volume
95K
Avg Turnover
2.753M
Top Brokers
AVA/NON
VWAP
31.9
Avg Volume
99K
Avg Turnover
3.161M
Top Brokers
NON/AVA
VWAP
32.8
Avg Volume
59K
Avg Turnover
1.939M
Top Brokers
NON/AVA
52 week summary
Price Range
27.1
Last
77.0
Beta
N/A
Market Cap
514.5M
Total Return
-48.2%
Trailing P/E
-1,353.2
Div Yield
0.0%
Shares Outstanding
17.4M
Next Earnings Date
13 Feb
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months -26.2%
Change 12 Months -53.9%
Volume Trend
Average Volume 10 vs 60 Days 144.5%
Price VS
52 Week High -62.6%
50 Day Moving Average -21.0%
200 Day moving Average -34.0%

Add article markers

Compare Moberg Pharma to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Peter Wolpert, CEO
  • Anna Ljung, CFO
  • Torbjörn Wärnheim, Director Pharmaceutical Innovation and Development
  • Executive board
  • Thomas Eklund, Chairman of the board
  • Sara Brandt
  • Torbjörn Koivisto
  • Geert Cauwenbergh
  • Thomas Thomsen
  • Mattias Klintemar
Last updated: 2017-09-22 Source: Redeye
Major Owners Equity Votes
Östersjöstiftelsen 13.0%
13.0%
Staffan Persson 9.3%
9.3%
Avanza Pension 6.9%
6.9%
Grandeur Peak Fonder 4.7%
4.7%
Nordnet Pensionsförsäkring 2.6%
2.6%
Peter Wolpert 2.5%
2.5%
Anders Lundmark 1.8%
1.8%
Prioritet Finans 1.7%
1.7%
AXA 1.3%
1.3%
Livförsäkringsbolaget Skandia 1.3%
1.3%
Last updated: 2017-10-21 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
+ 0
0 Sales
- 0
Last 24 weeks
0 Purchases
+ 0
0 Sales
- 0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream FI
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • 4.9%
  • 6.2%
  • 6.2%
  • 12.7%
  • 8.6%
  • 6.1%
  •  
  • 0.88
  • 0.88
  • 0.00
  •  
  • 14.0
  •  
  • 484.8
  • 43.3
  • 43.3
  • 2.7
  • 2.4
  • 19.1
  • 28.2
  • 1.7
  •  
  • 84.4%
  • 3.1%
  • -46
  • 258
  • 0.6
  • 2014
  •  
  •  
  • 62
  • 42
  • 13
  • 0
  • 117
  •  
  • 1
  • 0
  • 0
  • 88
  • 0
  • 129
  • 0
  • 217
  • 25
  • 360
  •  
  •  
  • 13
  • 39
  • 0
  • 53
  • 3
  • 0
  • 0
  • 56
  • 0
  • 0
  • 304
  • 0
  • 304
  • 360
  • 2014
  • 200
  • -175
  • -8
  • 17
  • -4
  • 13
  • 8
  • 21
  • -8
  • -42
  • -8
  • 2014 Q4
  • 44
  • -41
  • 4
  • -2
  • 0
  • 0
  • 1
  • 0
  • -0
  • 0
  • 1
  • -1
  • -0
  • 2015
  •  
  • 7.8%
  • 10.4%
  • 10.1%
  • 16.3%
  • 12.3%
  • 9.0%
  •  
  • 1.80
  • 1.80
  • 0.00
  •  
  • 14.2
  •  
  • 896.3
  • 36.6
  • 39.8
  • 3.3
  • 3.1
  • 19.3
  • 25.4
  • 2.7
  •  
  • 88.8%
  • 0.4%
  • -42
  • 311
  • 0.7
  • 2015
  •  
  •  
  • 45
  • 52
  • 22
  • 0
  • 119
  •  
  • 1
  • 0
  • 0
  • 100
  • 0
  • 161
  • 0
  • 262
  • 16
  • 397
  •  
  •  
  • 3
  • 41
  • 0
  • 45
  • 0
  • 0
  • 0
  • 45
  • 0
  • 0
  • 353
  • 0
  • 353
  • 397
  • 2015
  • 286
  • -239
  • -11
  • 35
  • -9
  • 26
  • 11
  • 37
  • -17
  • -56
  • -13
  • 2015 Q1
  • 73
  • -56
  • 17
  • -2
  • 0
  • 0
  • 15
  • 0
  • -0
  • 0
  • 15
  • -4
  • 11
  • 2015 Q2
  • 92
  • -81
  • 11
  • -3
  • 0
  • 0
  • 8
  • 0
  • -0
  • 0
  • 8
  • -3
  • 6
  • 2015 Q3
  • 67
  • -53
  • 14
  • -3
  • 0
  • 0
  • 11
  • 0
  • -0
  • 0
  • 11
  • -2
  • 9
  • 2015 Q4
  • 54
  • -50
  • 4
  • -3
  • 0
  • 0
  • 1
  • 0
  • -0
  • 0
  • 1
  • -1
  • 0
  • 2016
  •  
  • 7.2%
  • 8.3%
  • 14.1%
  • 23.3%
  • 18.6%
  • 9.8%
  •  
  • 1.88
  • 1.88
  • 0.00
  •  
  • 17.4
  •  
  • 1,495.4
  • 30.3
  • 32.3
  • 3.0
  • 4.5
  • 19.2
  • 24.0
  • 1.8
  •  
  • 45.6%
  • 37.3%
  • 503
  • 1,065
  • 0.3
  • 2016
  •  
  •  
  • 86
  • 93
  • 42
  • 0
  • 221
  •  
  • 1
  • 0
  • 0
  • 173
  • 0
  • 827
  • 0
  • 1,001
  • 10
  • 1,232
  •  
  •  
  • 0
  • 75
  • 0
  • 75
  • 589
  • 7
  • 0
  • 671
  • 0
  • 0
  • 562
  • 0
  • 562
  • 1,232
  • 2016
  • 334
  • -256
  • -16
  • 62
  • -19
  • 44
  • 16
  • 59
  • -44
  • -755
  • -688
  • 2016 Q1
  • 69
  • -66
  • 3
  • -3
  • 0
  • 0
  • 1
  • 0
  • -8
  • 0
  • -7
  • 2
  • -6
  • 2016 Q2
  • 71
  • -38
  • 33
  • -2
  • 0
  • 0
  • 31
  • 0
  • 5
  • 0
  • 36
  • -8
  • 28
  • 2016 Q3
  • 104
  • -75
  • 29
  • -6
  • 0
  • 0
  • 23
  • 0
  • -6
  • 0
  • 17
  • -4
  • 13
  • 2016 Q4
  • 89
  • -77
  • 12
  • -5
  • 0
  • 0
  • 7
  • 0
  • -6
  • 0
  • 1
  • -3
  • -2
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 Q1
  • 105
  • -88
  • 17
  • -10
  • 0
  • 0
  • 7
  • 0
  • -10
  • 0
  • -3
  • 0
  • -3
  • 2017 Q2
  • 136
  • -126
  • 10
  • -10
  • 0
  • 0
  • 0
  • 0
  • -9
  • 0
  • -9
  • 2
  • -8
  • 2017 Q3 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 Q4 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q1 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q2 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q3 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q4 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q1 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q2 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q3 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q4 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-11-16 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.